Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness and safety of Campath-1H [alemtuzumab] as an induction agent in combination with tacrolimus monotherapy for prevention of graft rejection compared to tacrolimus in combination with MMF [mycophenolate mofetil] and steroids [corticosteroids] in cadaveric kidney transplantation

X
Trial Profile

Effectiveness and safety of Campath-1H [alemtuzumab] as an induction agent in combination with tacrolimus monotherapy for prevention of graft rejection compared to tacrolimus in combination with MMF [mycophenolate mofetil] and steroids [corticosteroids] in cadaveric kidney transplantation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Corticosteroids; Methylprednisolone; Mycophenolate mofetil; Prednisolone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2012 Actual patient number changed from 131 to 197 as reported by ClinicalTrials.gov.
    • 09 May 2007 Status change from in progress to completed.
    • 23 Nov 2005 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top